Tesorx Is A Privately Held Pharmaceutical Company Developing A First In Class Unmodified Oral Testosterone For Androgen Deficiencyit Is In The Process Of Completing A Phase Two Clinical Study And Is On Track To Commence Dosing For Phase Three By Early 2014 The Us Market For Topicaltransdermal And Injectible Testosterone Formulations Alone Is Currently Estimated At $2 1 Billion With Prescriptions Having Grown 90Over Five Yearsanalysts Project That The Entire Testosterone Market Is Expected To Hit $5 Billion By 2017A Safe And Effective Oral Treatment Regimen Remains The Main Unmet Need And Studies Suggest That It Could Cannibalize More Than 70Of Existing Treatments Once Introduced Into The Market
